Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives

Helicobacter pylori (H. pylori) is the main cause of gastric adenocarcinoma. However, the traditional antibiotic treatment of H. pylori is limited due to increased antibiotic resistance and low efficacy; low drug delivery efficiency and difficulties in eradicating H. pylori that is present intracell...

Full description

Saved in:
Bibliographic Details
Main Authors: Yongkang Lai, Wei Wei, Yiqi Du, Jie Gao, Zhaoshen Li
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Gut Microbes
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/19490976.2022.2120747
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849763443755712512
author Yongkang Lai
Wei Wei
Yiqi Du
Jie Gao
Zhaoshen Li
author_facet Yongkang Lai
Wei Wei
Yiqi Du
Jie Gao
Zhaoshen Li
author_sort Yongkang Lai
collection DOAJ
description Helicobacter pylori (H. pylori) is the main cause of gastric adenocarcinoma. However, the traditional antibiotic treatment of H. pylori is limited due to increased antibiotic resistance and low efficacy; low drug delivery efficiency and difficulties in eradicating H. pylori that is present intracellularly or in biofilms cause further setbacks. Biomaterials that can protect drugs against stomach acid, target lesions, control drug release, destroy biofilms, and exhibit unique antibacterial mechanisms and excellent biocompatibility have emerged as attractive tools for H. pylori eradication, particularly for drug-resistant strains. Herein, we review the virulence mechanisms, current drug treatments, and antibiotic resistance of H. pylori strains. Furthermore, recent advances in the development of biomaterials, including nanoparticles (such as lipid-based nanoparticles, polymeric nanoparticles, and inorganic nanoparticles), microspheres, and hydrogels, for effective and precise therapy of H. pylori and different types of therapeutic mechanisms, as well as future perspectives, have also been summarized.
format Article
id doaj-art-d863043706df4abeba2a389ef2bf403b
institution DOAJ
issn 1949-0976
1949-0984
language English
publishDate 2022-12-01
publisher Taylor & Francis Group
record_format Article
series Gut Microbes
spelling doaj-art-d863043706df4abeba2a389ef2bf403b2025-08-20T03:05:24ZengTaylor & Francis GroupGut Microbes1949-09761949-09842022-12-0114110.1080/19490976.2022.2120747Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectivesYongkang Lai0Wei Wei1Yiqi Du2Jie Gao3Zhaoshen Li4Department of Gastroenterology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaChanghai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Gastroenterology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaChanghai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Gastroenterology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaHelicobacter pylori (H. pylori) is the main cause of gastric adenocarcinoma. However, the traditional antibiotic treatment of H. pylori is limited due to increased antibiotic resistance and low efficacy; low drug delivery efficiency and difficulties in eradicating H. pylori that is present intracellularly or in biofilms cause further setbacks. Biomaterials that can protect drugs against stomach acid, target lesions, control drug release, destroy biofilms, and exhibit unique antibacterial mechanisms and excellent biocompatibility have emerged as attractive tools for H. pylori eradication, particularly for drug-resistant strains. Herein, we review the virulence mechanisms, current drug treatments, and antibiotic resistance of H. pylori strains. Furthermore, recent advances in the development of biomaterials, including nanoparticles (such as lipid-based nanoparticles, polymeric nanoparticles, and inorganic nanoparticles), microspheres, and hydrogels, for effective and precise therapy of H. pylori and different types of therapeutic mechanisms, as well as future perspectives, have also been summarized.https://www.tandfonline.com/doi/10.1080/19490976.2022.2120747Helicobacter pyloribiomaterialsnanoparticlesmicrosphereshydrogels
spellingShingle Yongkang Lai
Wei Wei
Yiqi Du
Jie Gao
Zhaoshen Li
Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives
Gut Microbes
Helicobacter pylori
biomaterials
nanoparticles
microspheres
hydrogels
title Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives
title_full Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives
title_fullStr Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives
title_full_unstemmed Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives
title_short Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives
title_sort biomaterials for helicobacter pylori therapy therapeutic potential and future perspectives
topic Helicobacter pylori
biomaterials
nanoparticles
microspheres
hydrogels
url https://www.tandfonline.com/doi/10.1080/19490976.2022.2120747
work_keys_str_mv AT yongkanglai biomaterialsforhelicobacterpyloritherapytherapeuticpotentialandfutureperspectives
AT weiwei biomaterialsforhelicobacterpyloritherapytherapeuticpotentialandfutureperspectives
AT yiqidu biomaterialsforhelicobacterpyloritherapytherapeuticpotentialandfutureperspectives
AT jiegao biomaterialsforhelicobacterpyloritherapytherapeuticpotentialandfutureperspectives
AT zhaoshenli biomaterialsforhelicobacterpyloritherapytherapeuticpotentialandfutureperspectives